瑞舒伐他汀对老年冠心病患者造影剂肾病的预防作用和对血脂的影响

    Preventive effect of rosuvastatin on contrast-induced nephropathy and blood lipids in elderly patients with coronary heart disease

    • 摘要: 目的 观察瑞舒伐他汀对老年冠心病患者造影剂肾病(CIN)的预防作用和对血脂的影响。方法 2014年1月~2014年12月确诊的老年冠心病患者114(男67,女47)例,年龄61~83岁,随机分为常规治疗组(n=57)和瑞舒伐他汀组(n=57)。瑞舒伐他汀组在常规治疗的基础上加服瑞舒伐他汀,每晚20 mg,连续8周。两组分别于造影前、造影后24 h、72 h和7 d测定尿素氮(BUN)及血肌酐(SCr)水平并计算内生肌酐清除率(CCr),同时测定血脂水平。结果 造影前常规治疗组与瑞舒伐他汀组肾功能无显著差异,但瑞舒伐他汀组血脂明显低于常规治疗组(P<0.05,P<0.01)。常规治疗组造影后24 h、72 h BUN和SCr明显高于造影前(P<0.05,P<0.01),而CCr则明显降低(P<0.01),血脂无明显变化,这些变化均于7 d后恢复正常。瑞舒伐他汀组造影后仅SCr在24 h、72 h较造影前升高(P<0.05),BUN和CCr无明显变化。常规治疗组发生CIN 6例(11%)于7 d后恢复,瑞舒伐他汀组无发生CIN病例,与常规治疗组CIN发生率比较有显著差异(P<0.05)。两组造影前后血脂均无显著变化。两组不良反应发生率无统计学差异。结论 瑞舒伐他汀对老年冠心病患者具有降血脂作用和对CIN有显著预防作用。

       

      Abstract: AIM To investigate the preventive effect of rosuvastatin on preventive contrast-induced nephropathy (CIN) and blood lipid levels in elderly patients with coronary heart disease. METHODSFrom January-December 2014, 114 patients (67 male, 47 female) with coronary heart disease, aged 61-83 years, were randomly divided into conventional treatment group (n=57) and rosuvastatin group (n=57). The rosuvastatin group was given rosuvastatin orally, 20 mg/night for 8 weeks. Blood urea nitrate (BUN) and serum creatinine (SCr) levels were measured in both groups, respectively, before surgery and 24 h, 72 days and 7 days after surgery. Endogenous creatinine clearance rate (CCr) was calculated and blood lipid levels were tested at the same time. RESULTSNo difference in renal function was observed between conventional group and rosuvastatin group before surgery; however, serum lipids were significantly lower in the rosuvastatin group (P<0.05, P<0.01). In the conventional treatment group, BUN and SCr 24 h and 72 h after surgery were significantly higher than those before surgery (P<0.05, P<0.01), CCr decreased significantly (P<0.01) and no significant change was found in blood lipids. These changes returned to normal after 7 days. In the rosuvastatin group, SCr increased (P<0.05) and no significant change was found in BUN and CCr 24 h and 72 h after surgery. There were six cases (11%) of CIN in the conventional group and they recovered after 7 days, and no CIN case in the rosuvastatin group. There were no significant changes in blood lipids in both groups before and after surgery. Difference in the incidence of adverse reactions between groups was not statistically significant. CONCLUSIONRosuvastatin reduces the effect of serum lipids and has a beneficial preventive effect of CIN in elderly patients with coronary heart disease.

       

    /

    返回文章
    返回